HLHerbert Lannon

Herbert Lannon

*This is an algorithmically generated author record based on publicly available information.

Herbert Lannon has a total of 26 co-authors. Here are the top co-authors by number of shared publications:

  • David J. Friedman

    Renal Division, Beth Israel Deaconess Medical Center, Boston, USA

    2 shared publications
  • Leny Dias

    Division of Nephrology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA

    2 shared publications
  • Martin R. Pollak

    Division of Nephrology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA; Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA

    2 shared publications
  • Seth L. Alper

    Division of Nephrology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA; Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA

    2 shared publications
  • Shrijal S. Shah

    Department of Nephrology, Beth Israel Deaconess Medical Center, USA

    2 shared publications
  • Alexander Alexeyev

    CytoTronics Inc., Boston, USA

    1 shared publication

Latest Publications

  • Open Access

    A semiconductor 96-microplate platform for electrical-imaging based high-throughput phenotypic screening

    by Shalaka Chitale, Wenxuan Wu, Avik Mukherjee, Herbert Lannon, Pooja Suresh, Ishan Nag, Christina M. Ambrosi, Rona S. Gertner, Hendrick Melo, Brendan Powers, et al.

    High-content imaging for compound and genetic profiling is popular for drug discovery but limited to endpoint images of fixed cells. Conversely, electronic-based devices offer label-free, live cell functional information but suffer from limited spatial resolution or throughput. Here, we introduce a semiconductor 96-microplate platform for high-resolution, real-time impedance imaging. Each well features 4096 electrodes at 25 µm spatial resolution and a miniaturized data interface allows 8× parallel plate operation (768 total wells) for increased throughput. Electric field impedance measurements capture >20 parameter images including cell barrier, attachment, flatness, and motility every 15 min during experiments. We apply this technology to characterize 16 cell types, from primary epithelial to suspension cells, and quantify heterogeneity in mixed co-cultures. Screening 904 compounds across 13 semiconductor microplates reveals 25 distinct responses, demonstrating the platform’s potential for mechanism of action profiling. The scalability and translatability of this semiconductor platform expands high-throughput mechanism of action profiling and phenotypic drug discovery applications.


  • Apolipoprotein L1 (APOL1) risk variant toxicity depends on the haplotype background

    by Herbert Lannon, Shrijal S. Shah, Leny Dias, Daniel Blackler, Seth L. Alper, Martin R. Pollak, David J. Friedman


  • APOL1 Kidney Risk Variants Induce Cell Death via Mitochondrial Translocation and Opening of the Mitochondrial Permeability Transition Pore

    by Shrijal S. Shah, Herbert Lannon, Leny Dias, Jia-Yue Zhang, Seth L. Alper, Martin R. Pollak, David J. Friedman

    Significance Statement: Some variants in APOL1 are associated with high CKD rates in African Americans, but the molecular mechanism of disease remains elusive. Previous studies demonstrated that expression of APOL1 risk variants is associated with mitochondrial dysfunction. In this study, the authors show that import of APOL1 protein into mitochondria is essential for risk variant–mediated cytotoxicity, and map the APOL1 import pathway. They found that whereas APOL1 is mostly monomeric, risk variant APOL1 can form large oligomers and cause opening of the mitochondrial permeability transition pore, ultimately leading to cell death. This difference in propensity of different variants to oligomerize could help explain APOL1 risk variants’ gain-of-function biology despite a recessive mode of inheritance. Understanding APOL1 trafficking and interactions could help inform new therapeutic approaches. Background: Genetic Variants in Apolipoprotein L1 (APOL1) are associated with large increases in CKD rates among African Americans. Experiments in cell and mouse models suggest that these risk-related polymorphisms are toxic gain-of-function variants that cause kidney dysfunction, following a recessive mode of inheritance. Recent data in trypanosomes and in human cells indicate that such variants may cause toxicity through their effects on mitochondria. Methods: To examine the molecular mechanisms underlying APOL1 risk variant–induced mitochondrial dysfunction, we generated tetracycline-inducible HEK293 T-REx cells stably expressing the APOL1 nonrisk G0 variant or APOL1 risk variants. Using these cells, we mapped the molecular pathway from mitochondrial import of APOL1 protein to APOL1-induced cell death with small interfering RNA knockdowns, pharmacologic inhibitors, blue native PAGE, mass spectrometry, and assessment of mitochondrial permeability transition pore function. Results: We found that the APOL1 G0 and risk variant proteins shared the same import pathway into the mitochondrial matrix. Once inside, G0 remained monomeric, whereas risk variant proteins were prone to forming higher-order oligomers. Both nonrisk G0 and risk variant proteins bound components of the mitochondrial permeability transition pore, but only risk variant proteins activated pore opening. Blocking mitochondrial import of APOL1 risk variants largely eliminated oligomer formation and also rescued toxicity. Conclusions: Our study illuminates important differences in the molecular behavior of APOL1 nonrisk and risk variants, and our observations suggest a mechanism that may explain the very different functional effects of these variants, despite the lack of consistently observed differences in trafficking patterns, intracellular localization, or binding partners. Variant-dependent differences in oligomerization pattern may underlie APOL1’s recessive, gain-of-function biology.